SURVIVIN SPECIFIC T-CELL RECEPTOR TARGETING TUMOR BUT NOT T CELLS
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
N/A
Issued Date -
N/A
app pub date -
Oct 30, 2015
filing date -
Oct 31, 2014
priority date (Note) -
Published
status (Latency Note)
Importance
Abstract
Embodiments of the disclosure concern engineered T cell receptors that are specific for the survivin tumor antigen but do not have “on-target off tumor” toxicity. In particular embodiments, particular alpha and beta chains are utilized in engineered T cell receptors for cell therapy that have effective anti-tumor activity but lack fratricidal effects. Methods, compositions, and kits are provided herein.
First Claim
Family
International Classification(s)
- [Classification Symbol]
- [Patents Count]
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully